Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients

• Main Authors: Alexander V. Lavrov (Author), Ekaterina Yu. Chelysheva (Author), Elmira P. Adilgereeva (Author), Oleg A. Shukhov (Author), Svetlana A. Smirnikhina (Author), Konstantin S. Kochergin-Nikitsky (Author), Valentina D. Yakushina (Author), Grigory A. Tsaur (Author), Sergey V. Mordanov (Author), Anna G. Turkina (Author), Sergey I. Kutsev (Author)
• Format: Book
• Published: BMC, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Approximately 5-20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy. Gene polymorphisms, expression and microRNAs are known to be involved in the pa...